Skip to main content

Table 4 Short-term efficacy of exploratory therapy

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Short-term efficacy

Number of patients (Percent)

Complete response (CR)

2 (20.0)

Partial response (PR)

0 (0)

Stable disease (SD)

3 (30.0)

Progressive disease (PD)

5 (50.0)

  1. Short-term efficacy was classified by modified Response Evaluation Criteria in Solid Tumors version 1.1(RECIST 1.1)